Greetings Amanda - thanks for the question and I'm glad to be part of this group. I have just been diagnosed with metastatic castrate resistant prostate cancer (mCRPC) from my PSMA PET scan. My current team is a urologist, radiation oncologist and primary care physician. I am scheduled to see a medical oncologist in early November. My team is currently recommending Xtandi first and when is stops working, follow with Taxotere. However, they also are clear there is considerable debate in the prostate cancer medical community of using second generation hormone therapy first vs. a more aggressive approach of chemo first, then follow with second generation hormone therapy. They are open to more discussion on this before we decide. Based on what I have read, new research and observations have shown longer survival rates with a more aggressive approach. At Mayo, Dr, Eugene Kwon has been a leader in the more aggressive approach. This is a very important topic for those of us with mCRPC and would I appreciate any insight/knowledge/research to help inform the best path forward. Your help is greatly appreciated as this is time critical.